|
April 12 , 2005
MEDICURE TO PRESENT AT EUROPEAN BIOTECH CONFERENCES
WINNIPEG, Manitoba Ð (April 12, 2005).
WINNIPEG, Manitoba - (April 12, 2005) - Medicure Inc. (TSX:MPH/Amex:MCU), a cardiovascular drug discovery and development company, is pleased to announce that it’s President & CEO, Dr. Albert Friesen, PhD, will be presenting at two upcoming international Biotech conferences. The two conferences, the World Life Sciences Forum/BioVision and BioSquare will run simultaneously in Lyon France, attracting opinion-leaders and decision makers from the pharmaceutical, biotechnology, and investment communities.
Dr. Friesen will be a guest speaker at a plenary session at the World Life Sciences Forum entitled, “Women, Health, and Science”. Dr. Friesen will speak on cardiovascular disease in women, and the opportunity for Medicure’s lead product, MC-1, to improve cardiac outcomes in women. The “Women, Health, and Science” plenary session is scheduled at 2 pm on April 14 th at the Hilton Hotel in Lyon.
Medicure will also be presenting at BioSquare, Europe’s leading biotechnology partnering event. BioSquare 2005 offers a unique platform for the top management of biotechnology companies to meet with key research and business development executives from the pharmaceutical and finance industries. Dr. Friesen will deliver Medicure’s corporate presentation on Friday, April 15, 2005 at 10:45 am in Room Rhone 3A, Level 1 in the International Convention Center.
About Medicure Inc.
Medicure Inc. is a cardiovascular drug discovery and development Company focused on developing effective therapeutics for unmet needs in the field of cardiovascular medicine, the largest pharmaceutical market sector. The Company's solid position in this field is supported by the following attributes:
- Cardiovascular focused pipeline: a global market of over US $70 billion
- Two drugs - MC-1 & MC-4232 - in advanced Phase II trials
- Two positive Phase II trials completed
- Unique products addressing major markets not adequately served by existing drugs
- Second combination product, MC-4262 is entering development stage
- Dual action antithrombotic, MC-45308, in preclinical testing
The Company's financial position remains solid, providing sufficient resources to complete the ongoing Phase II studies, and to advance the lead candidates up to pivotal Phase III studies.
Medicure also has a medicinal chemistry based Drug Discovery program focused on discovery and advancement of novel small molecule, anti-ischemics and anti-thrombotics towards human clinical studies.
This press release contains forward-looking statements that involve risks, which may cause actual results to differ materially from the statements made, and accordingly may be deemed to be forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are made as of the date hereof, and the Company disclaims any intention and has no obligation or responsibility to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
For more information, please contact:
Derek Reimer
Chief Financial Officer
Hogan Mullally
Manager of Investor & Public Relations
Medicure Inc.
888-435-2220
204-488-9823 fax
info@medicure.com
Back to News Releases
|
|
